HK$99.70
0.10%
Hong Kong, Sep 25, 04:08 pm HKT. Closed.
ISIN
KYG4818G1010
Symbol
1801
Index

Innovent Biologics Target price 2026 - Analyst rating & recommendation

Innovent Biologics Classifications & Recommendation

Buy
92%
Hold
8%

Innovent Biologics Price Target

Target Price HK$131.58
Price HK$99.70
Potential
Number of Estimates 29
29 Analysts have issued a price target Innovent Biologics 2027 . The average Innovent Biologics target price is HK$131.58. This is higher than the current stock price. The highest price target is
HK$157.08 57.55%
register free of charge
, the lowest is .
A rating was issued by 38 analysts: 35 Analysts recommend Innovent Biologics to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Innovent Biologics stock has an average upside potential 2027 of . Most analysts recommend the Innovent Biologics stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion HK$ 15.24 22.11
38.42% 45.11%
EBITDA Margin 11.14% 17.17%
181.59% 54.19%
Net Margin 6.24% 12.81%
721.13% 105.35%

35 Analysts have issued a sales forecast Innovent Biologics 2026 . The average Innovent Biologics sales estimate is

HK$22.1b
unlock
. This is
20.49% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$24.3b 32.37%
unlock
, the lowest is
HK$18.8b 2.20%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$15.2b 38.42%
2026
HK$22.1b 45.11%
unlock
2027
HK$27.3b 23.64%
unlock
2028
HK$32.3b 17.98%
unlock
2029
HK$39.8b 23.30%
unlock
2030
HK$46.3b 16.34%
unlock
2031
HK$53.3b 15.16%
unlock
2032
HK$59.6b 11.86%
unlock
2033
HK$64.5b 8.24%
unlock

34 Innovent Biologics Analysts have issued a net profit forecast 2026. The average Innovent Biologics net profit estimate is

HK$2.8b
unlock
. This is
96.68% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$4.2b 194.73%
unlock
, the lowest is
HK$1.6b 13.35%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$951m 959.75%
2026
HK$2.8b 197.93%
unlock
2027
HK$4.3b 51.54%
unlock
2028
HK$5.9b 36.44%
unlock
2029
HK$4.7b 18.94%
unlock
2030
HK$6.4b 35.08%
unlock
2031
HK$7.0b 8.68%
unlock
2032
HK$9.6b 38.21%
unlock
2033
HK$12.1b 26.13%
unlock

Net Margin

2025 6.24% 721.13%
2026
12.81% 105.35%
unlock
2027
15.70% 22.56%
unlock
2028
18.15% 15.61%
unlock
2029
11.93% 34.27%
unlock
2030
13.86% 16.18%
unlock
2031
13.08% 5.63%
unlock
2032
16.16% 23.55%
unlock
2033
18.83% 16.52%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ 0.55 1.63
885.71% 196.36%
P/E 61.20
EV/Sales 6.94

34 Analysts have issued a Innovent Biologics forecast for earnings per share. The average Innovent Biologics EPS is

HK$1.63
unlock
. This is
103.75% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$2.44 205.00%
unlock
, the lowest is
HK$0.94 17.50%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$0.55 885.71%
2026
HK$1.63 196.36%
unlock
2027
HK$2.47 51.53%
unlock
2028
HK$3.37 36.44%
unlock
2029
HK$2.73 18.99%
unlock
2030
HK$3.69 35.16%
unlock
2031
HK$4.01 8.67%
unlock
2032
HK$5.54 38.15%
unlock
2033
HK$6.99 26.17%
unlock

P/E ratio

Current 124.63 0.19%
2026
61.20 50.89%
unlock
2027
40.38 34.02%
unlock
2028
29.60 26.70%
unlock
2029
36.52 23.38%
unlock
2030
27.03 25.99%
unlock
2031
24.88 7.95%
unlock
2032
18.00 27.65%
unlock
2033
14.27 20.72%
unlock

Based on analysts' sales estimates for 2026, the Innovent Biologics stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 8.36 34.79%
2026
6.94 16.97%
unlock
2027
5.61 19.12%
unlock
2028
4.76 15.24%
unlock
2029
3.86 18.90%
unlock
2030
3.32 14.04%
unlock
2031
2.88 13.17%
unlock
2032
2.58 10.61%
unlock
2033
2.38 7.61%
unlock

P/S ratio

Current 9.49 28.96%
2026
7.88 17.01%
unlock
2027
6.37 19.12%
unlock
2028
5.40 15.24%
unlock
2029
4.38 18.90%
unlock
2030
3.76 14.04%
unlock
2031
3.27 13.17%
unlock
2032
2.92 10.61%
unlock
2033
2.70 7.61%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today